Alyeska Investment Group, L.P. Fulcrum Therapeutics, Inc. Transaction History

Alyeska Investment Group, L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$2.26 - $3.8 $112,999 - $190,000	50,000 Added 32.86%	202,148 $667,000
Q1 2023 May 15, 2023	BUY	$2.83 - $13.99 $430,578 - $2.13 Million	152,148 New	152,148 $433,000
Q4 2020 Feb 16, 2021	BUY	$7.84 - $13.4 $1.91 Million - $3.27 Million	244,040 Added 116.9%	452,797 $5.3 Million
Q3 2020 Nov 16, 2020	BUY	$7.22 - $20.7 $961,747 - $2.76 Million	133,206 Added 176.31%	208,757 $1.66 Million
Q4 2019 Feb 14, 2020	SELL	$4.46 - $18.14 $333,224 - $1.36 Million	-74,714 Reduced 49.72%	75,551 $1.26 Million
Q3 2019 Nov 14, 2019	BUY	$6.64 - $14.89 $997,759 - $2.24 Million	150,265 New	150,265 $997,000

150

52.2M

6.91M

1.9M

Ticker FULC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,038,900
Market Cap $237M
Description
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...

Get notified when there are updates to the investment portfolio of Alyeska Investment Group, L.P., based on Form 13F filings with the SEC.

Stay updated on Alyeska Investment Group, L.P. with notifications on news.